ECASS

ECASS
Name	ECASS
Title	ECASS
Developer	European Stroke Organisation/Thrombolysis trial groups
Released	1990s
Latest release version	various editions
Programming language	Multiple
Operating system	Cross-platform
Genre	Clinical assessment tool

ECASS

ECASS is a standardized clinical and radiological framework developed to classify outcomes, hemorrhagic complications, and imaging findings in acute ischemic stroke trials. It is widely cited in literature originating from European Stroke Organisation trials, International Stroke Trial designs, and multicenter thrombolysis studies such as those coordinated by the European Cooperative Acute Stroke Study groups. The framework informs trial eligibility, safety monitoring, and regulatory submissions involving agents evaluated by agencies like the European Medicines Agency and the U.S. Food and Drug Administration.

Overview

ECASS provides definitions for symptomatic intracerebral hemorrhage, radiographic parenchymal hematoma subtypes, and standardized outcome measures aligned with instruments used in trials associated with National Institute of Neurological Disorders and Stroke, World Health Organization case ascertainment, and multinational consortia. The system interfaces with scales and instruments such as the National Institutes of Health Stroke Scale, the Modified Rankin Scale, and the Glasgow Coma Scale to harmonize safety endpoints across studies sponsored by entities including European Commission research programs, academic stroke centers like Charité – Universitätsmedizin Berlin, and cooperative groups such as the Stroke Therapy Academic Industry Roundtable. ECASS definitions have been incorporated into protocols from trials run by academic centers at University of Cambridge, Karolinska Institutet, University of Heidelberg, and industry sponsors including major pharmaceutical companies.

History and Development

The ECASS framework emerged from a sequence of randomized controlled trials in the 1990s that evaluated thrombolytic therapy after ischemic stroke. Early trials linked with investigators at University College London, University of Cincinnati, and University of Glasgow contributed imaging criteria and clinical endpoints now associated with ECASS. Subsequent iterations were refined through collaborations among principal investigators from European Stroke Organisation, trial steering committees chaired by clinicians affiliated with Imperial College London and Hôpital Pitié-Salpêtrière, and methodological advice from biostatisticians at institutions such as London School of Hygiene & Tropical Medicine. Consensus meetings involving representatives from the World Stroke Organization and regulatory reviewers from the European Medicines Agency led to harmonized definitions that reduced heterogeneity between trials sponsored by academic consortia and industry.

Methodology and Components

ECASS methodology combines neuroimaging classifications with clinical adjudication to define hemorrhagic transformation subtypes and symptomatic events. Radiological categories distinguish hemorrhagic infarction and parenchymal hematoma patterns on computed tomography and magnetic resonance imaging, integrating reporting standards used at centers like Charité – Universitätsmedizin Berlin and Karolinska Universitetssjukhuset. Clinical criteria link neurological deterioration measured by the National Institutes of Health Stroke Scale to imaging changes to operationalize "symptomatic intracerebral hemorrhage" for data safety monitoring boards convened by groups such as the Data Safety Monitoring Board model used in trials at University of Oxford. The ECASS schema also specifies time windows, baseline infarct volume thresholds, and exclusion criteria influenced by protocols from the PROACT and ATLANTIS studies and recommendations from the Stroke Therapy Academic Industry Roundtable.

Clinical and Scientific Applications

ECASS definitions are used in randomized trials of reperfusion therapies, registries led by organizations such as the European Stroke Organisation and the American Heart Association, and observational studies at tertiary centers including Massachusetts General Hospital and Mayo Clinic. The framework supports meta-analyses coordinated by consortia like the Individual Patient Data Meta-analysis initiatives and informs guideline statements from bodies such as the American Heart Association and European Stroke Organisation. ECASS criteria also appear in device trials overseen by regulatory authorities including the U.S. Food and Drug Administration and in post-marketing surveillance mandated by the European Medicines Agency for thrombolytic agents and thrombectomy devices manufactured by companies headquartered in regions including Basel and Boston.

Performance and Evaluation

Investigators have assessed ECASS performance by comparing interrater reliability for radiologic subclassification across neuroradiology units at institutions such as University of Toronto and Johns Hopkins Hospital, and by evaluating the association between ECASS-defined hemorrhagic events and functional outcomes measured with the Modified Rankin Scale in cohorts from Srinivasan Institute-affiliated centers and multicenter European registries. Meta-epidemiological studies including data pooled from trials coordinated by University of Glasgow and University of Munich have examined predictive validity, calibration for adverse event rates, and sensitivity/specificity relative to alternative definitions used in trials like NINDS rt-PA Stroke Trial.

Controversies and Limitations

ECASS classifications have provoked debate regarding reproducibility across centers with variable imaging protocols, MRI availability, and differing definitions adopted by regulatory submissions to agencies such as the European Medicines Agency and the U.S. Food and Drug Administration. Critics from academic groups at Harvard Medical School and University of California, San Francisco have argued that reliance on dichotomous symptomatic definitions may undercount clinically relevant hemorrhagic transformations observed in registries like those maintained by the American Heart Association. Methodological limitations include potential misclassification with early ischemic changes observed in trials from University of Erlangen and variability in adjudication practices among independent clinical events committees assembled by sponsors in Pharmaceutical industry–led trials. Ongoing initiatives by consortia such as the Stroke Imaging Repository aim to standardize imaging protocols and update ECASS nomenclature to reflect advances in perfusion imaging used at centers like Massachusetts General Hospital and Guy's and St Thomas' NHS Foundation Trust.

Category:Stroke